Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 16, 2013, Pages 5489-5499

  Powers, Alicia D ^a   Han, Wenquing ^a   Liu, Bi ^a   Palecek, Sean P ^a  

^a University of Wisconsin Madison   (United States)

Author keywords

Cancer diagnostic; Kinase activity; Kinase assay; Microfluidics

Indexed keywords

CANCER DIAGNOSTICS; EPIDERMAL GROWTH FACTOR RECEPTORS; FLUORESCENCE DETECTION; KINASE ACTIVITY; KINASE ASSAYS; MACROPOROUS HYDROGELS; MICROFLUIDIC ASSAYS; TYROSINE KINASE INHIBITOR;

AMINO ACIDS; BIOLOGICAL ORGANS; CELLS; DISEASES; ENZYME INHIBITION; HYDROGELS; MICROFLUIDICS; MULTIPLEXING; PATIENT TREATMENT; SUBSTRATES;

MICROCHANNELS;

5 ((2,6 DICHLOROBENZYL)SULFONYL) 3 ((3,5 DIMETHYL 4 ((2 (PYRROLIDIN 1 YLMETHYL)PYRROLIDIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) 1,3 DIHYDRO 2H INDOL 2 ONE; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; ABELSON KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE 1; INDOLE DERIVATIVE; MET PROTEIN, HUMAN; PHOSPHOTYROSINE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PTK2 PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; SULFONE;

ARTICLE; DRUG ANTAGONISM; EQUIPMENT; FLUORESCENCE; HUMAN; HYDROGEL; METHODOLOGY; MICROFLUIDIC ANALYSIS; SOLUTION AND SOLUBILITY; TUMOR CELL LINE;

CELL LINE, TUMOR; FLUORESCENCE; FOCAL ADHESION KINASE 1; HUMANS; HYDROGEL; INDOLES; MICROFLUIDIC ANALYTICAL TECHNIQUES; ONCOGENE PROTEINS V-ABL; PHOSPHOTYROSINE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOLUTIONS; SULFONES;

EID: 84879794925     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-013-6963-5     Document Type: Article

References (36)

1. Lechertier T, Hodivala-Dilke K (2012) Focal adhesion kinase and tumour angiogenesis. J Pathol 226:404-12
2. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC (2008) Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99:911-22
3. Jabbour E, Kantarjian H (2012) Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 87:1037-45
4. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Homer MJ (editors) (2007) Cancer survival among adults - US SEER Program, 1988-2001 - SEER publications. National Cancer Institute, SEER Program
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-17
6. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G (2012) Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795:1-34
7. Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thoracic Dis 3:10-8
8. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JCH, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109:E2127-33
9. Guilhot F, Roy L, Tomowiak C (2012) Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol 19:102-9
10. Galanina N, Bossuyt V, Harris LN (2011) Molecular predictors of response to therapy for breast cancer. Cancer J 17:96-103
11. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS (2011) (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 52:1684-9
12. Powers AD, Liu B, Lee AG, Palecek SP (2012) Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates. Analyst 137:4052-61
13. Lee AG, Beebe DJ, Palecek SP (2012) Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels. Biomed Microdevices 14:247-57
14. Ghosh G, Lee AG, Palecek SP (2009) Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Anal Biochem 393:205-14
15. Choi NW, Kim J, Chapin SC, Duong T, Donohue E, Pandey P, Broom W, Hill WA, Doyle PS (2012) Multiplexed detection of mRNA using porosity-tuned hydrogel microparticles. Anal Chem 84:9370-8
16. Hall B, Jones L, Forrest JA (2013) Measuring the kinetics and activity of adsorbed proteins: In vitro lysozyme deposited onto hydrogel contact lenses over short time periods. J Biomed Mater Res A 101:755-764
17. Li H, Leulmi RF, Juncker D (2011) Hydrogel droplet microarrays with trapped antibody-functionalized beads for multiplexed protein analysis. Lab Chip 11:528-34
18. Miyata T, Hayashi T, Kuriu Y, Uragami T (2012) Responsive behavior of tumor-marker-imprinted hydrogels using macromolecular cross-linkers. J Mol Recognit 25:336-43
19. Aurand ER, Lampe KJ, Bjugstad KB (2012) Defining and designing polymers and hydrogels for neural tissue engineering. Neurosci Res 72:199-213
20. Chikkaveeraiah BV, Bhirde AA, Morgan NY, Eden HS, Chen X (2012) Electrochemical immunosensors for detection of cancer protein biomarkers. ACS Nano 6:6546-61
21. Bogojevic D, Chamberlain MD, Barbulovic-Nad I, Wheeler AR (2012) A digital microfluidic method for multiplexed cell-based apoptosis assays. Lab Chip 12:627-34
22. Brueggemeier SB, Wu D, Kron SJ, and Palecek SP Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules 6, 2765-75
23. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W (1996) Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384:173-6
24. Sierra JR, Tsao M-S (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3:S21-35
25. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-203
26. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R (1979) Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713-33
27. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355
28. Druker BJ (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8:S14-8
29. Gan HK, Burgess AW, Clayton AHA, Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72:2924-30
30. Petch L, Bockholt S, Bouton A, Parsons J, Burridge K (1995) Adhesion-induced tyrosine phosphorylation of the p130 src substrate. J. Cell Sci 108:1371-1379
31. Zhu T (1998) Growth hormone stimulates the tyrosine phosphorylation and association of p125 focal adhesion kinase (FAK) with JAK2. FAK is not required for STAT-mediated transcription. J Biol Chem 273:10682-10689
32. Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG (2010) Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res 70:8299-308
33. Greener J, Li W, Ren J, Voicu D, Pakharenko V, Tang T, Kumacheva E (2010) Rapid, cost-efficient fabrication of microfluidic reactors in thermoplastic polymers by combining photolithography and hot embossing. Lab Chip 10:522-4
34. Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5:209-17
35. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-74
36. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3:317-25